Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of 15-year Risk of MASH (Metabolic Dysfunction-associated Steatohepatitis)-Related HCC (Hepatocellular Carcinoma) by Tissue Proteomic Profiling

NCT07332611 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT07332611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of 15-year Risk of MASH (Metabolic Dysfunction-associated Steatohepatitis)-Related HCC (Hepatocellular Carcinoma) by Tissue Proteomic Profiling
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
August 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mash-related hcc